Tag: CD30

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for. This year...

Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®)  in patients with cutaneous T-cell lymphoma (CTCL) were published in the...

Surrounded by fantastical and modernist landmarks designed by Antoni Gaudí, Barcelona, in the northeast of Spain, is a surreal wonderland where mansions look like...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...